OncoMatch/Clinical Trials/NCT05334277
Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
Is NCT05334277 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Furmonertinib and Furmonertinib for non-small cell lung cancer.
Treatment: Furmonertinib · Furmonertinib · Furmonertinib/Pemetrexed/Carboplatin · Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab — EGFR mutation positive advanced NSCLC patients with uncleared ctDNA have poor prognosis, whether they can benefit from combination therapy has not been reported. This study aims to investigate the efficacy and safety of combination therapy compared with furmonertinib monotherapy in advanced EGFR mutant NSCLC with uncleared circulating tumor cell DNA.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR exon 19 deletion
Patient with EGFR 19Del or L858R mutation diagnosed histologically or cytologically and confirmed by ctDNA
Required: EGFR L858R
Patient with EGFR 19Del or L858R mutation diagnosed histologically or cytologically and confirmed by ctDNA
Excluded: EGFR 20 exon insertion
Confirmed EGFR 20 exon insertion mutations at any time after the initial diagnosis [excluded]
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: EGFR tyrosine kinase inhibitor
Any Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI)
Cannot have received: systemic anti-cancer therapy
Exception: except neoadjuvant or adjuvant therapy before 6 months prior to the first dose
Prior treatment with any systemic anti-cancer therapy for advanced Non-Small Cell Lung Cancer (NSCLC) not amenable to curative surgery or radiation including chemotherapy, biologic therapy, target therapy, immunotherapy, or any investigational drug, except neoadjuvant or adjuvant therapy before 6 months prior to the first dose
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05334277 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require EGFR?
Yes, EGFR exon 19 deletion is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR L858R is a required biomarker for enrollment.
Are patients with EGFR alterations eligible?
No. EGFR 20 exon insertion is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages